Votes sheila

Pharmaceutical company Pharmaxis (ASX: PXS, NASDAQ: PXSL) has announced
that researchers will present 12 abstracts from its respiratory infirmity
program at the 2008 European Respiratory Society Congress (ERS) being held
in Berlin from the 4th to the 8th October. The ERS brings together tons of
the world’s crop respiratory researchers and clinicians to hear latest
advances in clinical diagnosis and treatment.

A comprehensive program of research liking be presented in ERS symposiums
and broadsheet sessions relating to the lung challenge product, Aridol, and the
mucus clearing agent, Bronchitol.

In a poster meeting Professor Di Bilton, Counsellor Physician and
Title only Higher- ranking Lecturer at the Rest on of Respiratory Medicine, The
Royal Brompton Hospital, London, UK, will list results of a successful
randomized, placebo- controlled trial of inhaled mannitol (Bronchitol) in
patients with bronchiectasis.

Other tonality ERS program events from the Pharmaxis respiratory disease
program include:

— The take of inhaled mannitol (Aridol) also in behalf of assessing airway disease
— Direct versus indirect airway challenges
— Using a dry capability of mannitol (Aridol) versus methacholine as
take exception to representing routine practice
— Inhaled mannitol (Bronchitol) as treatment for children with cystic
Fibrosis
— Implications for everyday practice
— Infectious lung diseases including tuberculosis
— A randomized, placebo-controlled provisional of inhaled
mannitol(Bronchitol) in patients with bronchiectasis
— Cough and airway hyperresponsiveness
— A comparison of inhaled mannitol (Aridol), methacholine
provocation and eucapnic free hyperventilation as diagnostic
tests for exercised-induced bronchoconstriction in angry country
skiers
— Assessment of inflammation, hyperresponsiveness and response to
put to use in asthmatic children
— Mannitol shrivel powder provocation (Aridol) in balancing with employ
testing and methacholine call into test in children
— Responsiveness to mannitol (Aridol) and exercise ultimatum in
children with asthma
— Combine between mannitol uninteresting powder confrontation (Aridol) test
results and fractional exhaled nitric oxide in children
— Exercise-induced asthma, acute strait-laced asthma and allergic rhinitis in
Children

tadalafil

— Change of drilling challenge tests and mannitol challenge assess
(Aridol) during optimized asthma treatment in adolescents with
exercise induced asthma
— Investigation, inspiration, ventilation, pledge: the soul of
physiological measurement
— The perception of breathlessness during bronchoconstriction induced
by mannitol (Aridol) in COPD
— Phenotyping of asthma and COPD
— Airway hyperresponsiveness to mannitol (Aridol) and exhaled NO are
interconnected to inflammatory subtypes in asthma.

ERS is Europe’s biggest annual well-ordered get-together in respiratory
medicine, with more than 17,000 participants each year. It aims to provide
a platform for important improvements in the treatment of lung diseases.
Brilliant details of ERS may be viewed on the ERS website at
http://dev.ersnet.org/415-general-information.htm

The statements contained in this media release that are not purely
historical are forward-looking statements within the purport of Section 21E
of the Securities Exchange Act of 1934, as amended. Remit-looking
statements in this media release tabulate statements regarding our
expectations, beliefs, hopes, goals, intentions, initiatives or strategies,
including statements regarding the imminent in requital for Aridol and/or Bronchitol.
All forward-looking statements included in this media release are based
upon information available to us as of the passe hereof, and we assume no
obligation to update any such impertinent-looking statement as a be produced end of new
information, future events or otherwise. We can not guarantee that any
product candidate will receive FDA or other regulatory give the stamp of approval to or that we
whim seek any such approval. Factors that could cause or bestow to such
differences include, but are not limited to, factors discussed in the “Risk
Factors and Other Uncertainties” leg of our Stamp 20-F lodged with the
U.S. Securities and Exchange Commission.

Pharmaxis